CLASRP

Across TCGA pan-cancer cohorts, CLASRP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLASRP data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CLASRP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLASRP expression acts as an unfavorable survival marker.

SCLC, HNSC, and COAD are the cancer types where CLASRP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
HNSC	OS	Median	All	0.133	0.687	<.001	24	view →
COAD	OS	Median	II,III,IV	0.444	0.793	.016	17	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLASRP–SCLC (OS)

Open the SCLC breakdown →